Programme Topics

  • Clinical application of 3D-Cancer map based on MRI-US fusion biopsy
  • Transperineal prostate biopsy: When and whom
  • Prostate cancer: Prognostic and therapeutic tissue markers
  • Where are we at in screening with PSA?
  • Use of biomarkers in selecting patients for active surveillance and focal ablation
  • Germline mutations in metastatic prostate cancer: Influence on treatment selection
  • Integrative oncology in prostate cancer
  • Dietary modifications after prostate cancer diagnosis
  • New approaches in non-surgical treatment of localized prostate cancer: HIFU, CRYO
  • Lu-177 in the treatment algorithm: How does it stack up?
  • Alpharidin in metastatic prostate cancer
  • Primary radiotherapy in metastatic prostate cancer
  • Therapeutic shift in hormone sensitive prostate cancer
  • Therapeutic options in non-metastatic castration-resistant prostate cancer
  • Case discussions -Prostate
  • Whats new in urinary cytology in the evaluation of urothelial cancer
  • VI-RADS (Vesical imaging-Reporting and data system)
  • Optimal and emerging treatments for NMIBC
  • Robotic cystectomy and urinary diversion
  • Future of surgery 2040
  • Bladder cancer and immunotherapy
  • Anti-FGFR agents for bladder cancer
  • Options for patients not eligible for cystectomy
  • Panel discussion: Optimizing management of high risk NMIBC – Case based discussion
  • Does maximal TURBT improve outcomes prior to cystectomy or neoadjuvant chemotherapy?
  • Pro/Con: Role of surgery in regional lymph node metastatic urothelial cancers
  • Case discussions -Bladder (30′)
  • New perspectives in the management of upper tract urothelial carcinoma
  • Neoadjuvant vs. adjuvant chemotherapy for UTUC
  • Rare hereditary renal cell carcinomas: What the radiologist need to know
  • Emerging biomarkers and therapeutic targets for renal cell carcinoma
  • Radiologic evaluation of sub types in renal masses
  • Surveillance for renal cell carcinoma: Is there a better way?
  • Interactive panel discussion: Integrating surgery and systemic therapy for locally advanced and metastatic RCC
  • Overview of challenges in adjuvant RCC trials
  • Case discussions -Kidney
  • Serum MicroRNA as a novel tumor marker for testicular germ cell tumor
  • Primary RPLND in stage I-IIa testicle tumors
  • Pro/Con: Minimally invasive RPLND
  • Update on role of surgical salvage/late relapse surgery in advanced GCT
  • Whats new in the systemic treatment of testicular cancer
  • Introduction to Molecular biology for clinicians
  • Basic consepts in immuno-oncology
  • Current status of pelvic lymphadenectomy: To do or not to do
  • Epigenetic regulation of OCT1 in castration resistant prostate cancer cells
  • Urobiome and bladder cancer: a new era for research
  • Perineal approach to prostate – Why? When?
  • Updated bilateral adrenectomy, use of ICG